ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201529-06-2023
29-06-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under Insider Trading Regulations27-06-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201527-06-2023
Zydus Lifesciences picks up equity in Mylab Discovery Solutions for 106 crore
The acquisition will help Zydus participate in the growing diagnostics space24-06-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Closure of Trading Window
Intimation of Trading Window Closure24-06-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Institutional Investors' Conference21-06-2023
Zydus Lifesciences gets USFDA nod for generic acne-treating drug
Zydus Lifesciences on Monday said it has received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-release tablets used for treatment of moderate to severe acne. The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing. The tablet is used for treatment of moderate to severe acne in people aged 12 years and above. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company said.19-06-2023
Zydus Lifesciences gains on USFDA's no observations for Ahmedabad unit
The US health regulator inspected the Indian firm's injectables manufacturing facility from June 5 to 13, 202314-06-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under Insider Trading Regulations10-06-2023
Zydus begins Phase-IV trial for non-alcoholic fatty liver disease drug
Saroglitazar Mg has been studied in two well-controlled Phase 3 clinical trials in patients with NAFLD and NASH in India09-06-2023